Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.82
- Piotroski Score 4.00
- Grade Hold
- Symbol (BMY)
- Company Bristol-Myers Squibb Company
- Price $49.13
- Changes Percentage (1.84%)
- Change $0.89
- Day Low $48.21
- Day High $49.15
- Year High $59.83
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
- Last Earnings 09/10/2024
- Ex-Dividend for 5/16 Dividend 10/04/2024
- Dividend Payable 11/01/2024
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $66.50
- High Stock Price Target $85.00
- Low Stock Price Target $41.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.10
- Trailing P/E Ratio -13.38
- Forward P/E Ratio -13.38
- P/E Growth -13.38
- Net Income $8.03 B
Income Statement
Quarterly
Annual
Latest News of BMY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Bristol-Myers Squibb Company (BMY) The Best Beaten Down Dividend Stocks to Invest in Now?
Bristol-Myers Squibb (NYSE:BMY) is a top beaten-down dividend stock. Despite challenges, dividend stocks remain strong, attracting investors with stable business models and cash flows. BMY offers soli...
By Yahoo! Finance | 1 week ago -
Bloomsbury Publishing's (LON:BMY) investors will be pleased with their splendid 259% return over the last five years
Investing in stocks can yield gains exceeding 100% or result in a complete loss. Bloomsbury Publishing saw its stock price surge by 214% in five years. Examining EPS growth and shareholder returns is ...
By Yahoo! Finance | 2 weeks ago -
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb Co has shown strong financial performance and innovation in drug development, especially in immuno-oncology. Despite U.S. market dependence and patent challenges, global expansion...
By Yahoo! Finance | 1 month ago
